National Bank of Canada FI Buys 82,834 Shares of DexCom, Inc. (NASDAQ:DXCM)

National Bank of Canada FI grew its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 40.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 286,955 shares of the medical device company's stock after purchasing an additional 82,834 shares during the period. National Bank of Canada FI owned approximately 0.07% of DexCom worth $19,237,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of DXCM. Two Sigma Advisers LP lifted its holdings in DexCom by 182.7% during the 3rd quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company's stock worth $76,659,000 after purchasing an additional 739,000 shares in the last quarter. Quarry LP lifted its holdings in shares of DexCom by 9,076.0% in the third quarter. Quarry LP now owns 4,588 shares of the medical device company's stock worth $308,000 after buying an additional 4,538 shares in the last quarter. Royal London Asset Management Ltd. boosted its position in shares of DexCom by 3.6% in the third quarter. Royal London Asset Management Ltd. now owns 163,238 shares of the medical device company's stock valued at $10,943,000 after acquiring an additional 5,733 shares during the period. Motley Fool Asset Management LLC grew its stake in DexCom by 168.7% during the third quarter. Motley Fool Asset Management LLC now owns 272,622 shares of the medical device company's stock valued at $17,993,000 after acquiring an additional 171,150 shares in the last quarter. Finally, Motley Fool Wealth Management LLC increased its holdings in DexCom by 157.1% during the 3rd quarter. Motley Fool Wealth Management LLC now owns 295,856 shares of the medical device company's stock worth $19,834,000 after acquiring an additional 180,775 shares during the period. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Trading Up 1.3 %

DXCM stock traded up $1.00 during trading on Tuesday, hitting $79.41. 2,969,405 shares of the company traded hands, compared to its average volume of 3,895,421. The company has a 50-day moving average of $72.77 and a 200-day moving average of $85.41. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The firm has a market capitalization of $31.02 billion, a PE ratio of 47.55, a P/E/G ratio of 2.38 and a beta of 1.12.

Insider Activity

In related news, EVP Sadie Stern sold 4,259 shares of the business's stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares in the company, valued at $5,320,178.16. The trade was a 5.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.30% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on DXCM shares. Wells Fargo & Company raised their price target on shares of DexCom from $80.00 to $90.00 and gave the company an "overweight" rating in a report on Friday, October 25th. Piper Sandler restated an "overweight" rating and set a $90.00 target price on shares of DexCom in a research report on Monday, August 26th. JPMorgan Chase & Co. lifted their price target on DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a research report on Friday, October 25th. StockNews.com cut shares of DexCom from a "buy" rating to a "hold" rating in a research report on Saturday, November 2nd. Finally, Canaccord Genuity Group lifted their target price on shares of DexCom from $89.00 to $99.00 and gave the company a "buy" rating in a research report on Monday. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, DexCom has a consensus rating of "Moderate Buy" and a consensus price target of $101.88.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.